Raymond James initiated coverage of Biohaven (BHVN) with a Strong Buy rating and $75 price target Shares, down 60% year-to-date, have been unfairly punished after a string of “minor setbacks”, the analyst tells investors in a research note. Biohaven possesses what can fairly be described as one of biotech’s most diverse and deep pipelines, though the firm sees three key value drivers moving forward – Kv7 BHV-7000 for focal epilepsy, IgG degrader BHV-1300 for Graves’ disease, and troriluzole for spinocerebellar ataxia, the firm adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHVN:
- BHVN Lawsuit Alert! Class Action Lawsuit Against Biohaven Ltd.
- 3 Best Stocks to Buy Now, 8/25/2025, According to Top Analysts
- Optimistic Buy Rating for Biohaven Ltd. Driven by Regulatory Progress and Market Potential of Troriluzole
- Biohaven Ltd. Awaits FDA Decision on Troriluzole
- RBC says PTC Therapeutics CRL may signal difficulty for Biohaven